Diagnosis and Therapeutic Strategy for Papillary Thyroid Microcarcinoma

Jen-Der Lin, MD; Szu-Tah Chen, MD; Tzu-Chieh Chao, MD, PhD; Chuen Hsueh, MD; Hsiao-Fen Weng, MS

Hypothesis: Total thyroidectomy followed by radioactive iodine I 131 treatment is effective in papillary thyroid microcarcinoma (PTM) with lymph node or extrathyroid invasion.

Design: Retrospective study.

Setting: Chang Gung Medical Center, Linkou, Taiwan.

Patients: A total of 227 patients with PTM, categorized into high-risk (n=12) and low-risk (n=215) groups according to age, metastases, extent, and size criteria.

Interventions: Diagnosis and treatment of PTM.

Main Outcome Measures: Time and method of diagnosis, operative method, metastases, and survival.

Results: In 51 patients, PTM was identified on preoperative fine-needle aspiration cytology; in 75 patients, diagnosed in frozen sections during operation; and in 101 patients, diagnosed incidentally in the final histopathological examination. Among these 3 groups, 18% (9/51), 17% (13/75), and 78% (79/101), respectively, underwent subtotal thyroidectomy or lobectomy for tumors. Four cases (1.8%) displayed distant metastases at diagnosis. Only 0.9% of patients with PTM (2 of 227) died of thyroid cancer. One hundred eighty-nine cases of PTM were confined to the thyroid, 22 had lymph node metastases, and 16 showed extrathyroid extension, including soft-tissue invasion and distant metastases. Sex, operative methods, follow-up status, and mortality showed differences in these groups. Five of 227 patients remained in non–disease-free status at follow-up.

Conclusions: Approximately 10% of PTMs exhibited progressive clinical courses, while less than 1% resulted in mortality. Age, sex, and postoperative thyroglobulin level were the main prognostic factors in the high-risk group of patients with PTM. Conservative treatment of the incidental finding of PTM after suitable postoperative assessment is justified.

Arch Surg. 2005;140:940-945

Wide variations exist in surgical methods as well as use of postoperative radioactive iodine I 131 (131I) treatment and follow-up in papillary thyroid microcarcinoma (PTM). Before consensus is attained in treating this indolent disease, specific facts concerning clinical presentation, diagnosis, long-term follow-up, and PTM treatment results in different populations are needed.1 Autopsy findings have shown prevalence rates of thyroid microcarcinoma ranging from 5.6% to 35.6%.2-4 Although most patients with thyroid microcarcinoma were reported to have displayed a benign clinical course, PTM with an invasive course was also demonstrated.5-6 The clinical behaviors of papillary and follicular thyroid carcinoma are different. The present study retrospectively evaluated 1516 cases of papillary thyroid carcinomas, including 227 patients with PTM who were treated at Chang Gung Memorial Hospital in Linkou, Taiwan. The goals of this retrospective investigation included assessing therapeutic strategies for PTM, including operation and use of 131I treatment in the high-risk group. The study was also aimed at elucidating clinical manifestations of PTM along with the prognostic factors linked to PTM by comparison with larger thyroid carcinomas.

Author Affiliations: Division of Endocrinology and Metabolism, Department of Internal Medicine (Drs Lin, Chen, and Ms Weng), Department of General Surgery (Dr Chao), and Department of Pathology (Dr Hsueh), Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan.

METHODS

During 25 years, from January 1, 1977, to December 31, 2002, a total of 2003 patients with thyroid carcinoma, including 1516 with papillary thyroid carcinoma, underwent treatment and were followed up at Chang Gung Medical Center. Among them, 1370 had recorded tumor measurements. This study ex-
cluded the other 146 cases with unknown tumor size. Of the recorded tumors, 227 (16.6%) were PTM, defined as papillary thyroid cancer not larger than 1.0 cm (Figure 1).

Of the 227 patients with PTM, 168 underwent preoperative thyroid ultrasonography with fine-needle aspiration cytology (FNAC) examinations (Figure 2). In Chang Gung Medical Center, most patients diagnosed as having well-differentiated thyroid cancer before or during operation received nearly total thyroidectomy. Otherwise, subtotal thyroidectomy or lobectomy was performed for benign thyroid disorders. During the operation, frozen sections were taken in 159 patients with PTM. Figure 2 illustrates distribution of the 227 patients with PTM diagnosed through FNAC, frozen section during the surgery, or final histopathological examination.

The 227 cases were categorized into 3 patient groups. Group 1 (51 cases) comprised cases of PTM diagnosed on preoperative FNAC as papillary carcinoma or follicular neoplasm. Group 2 (75 cases) represented PTM diagnosed in frozen sections during operation. Group 3 (101 cases) included incidental findings diagnosed on final histopathological examination. An incidental finding of PTM was defined as the finding of PTM during surgery for benign thyroid disorders and preoperative FNAC or frozen section during operation for benign lesions. Group 3 contained 37 patients not undergoing FNAC or frozen section. Most of these patients received consistent follow-up in the Division of Endocrinology and Metabolism.

All patients were also categorized into high- and low-risk groups according to age, metastases, extent, and size criteria. After the operation, most patients underwent long-term thyroid hormone replacement or suppressive treatment. Cancer assessments involved a 2- to 5-mCi (74- to 185-MBq) 131I whole-body scan and chest radiography. Serum thyroglobulin (Tg) levels were assessed every 6 to 12 months. Postoperative serum Tg levels were detected by an immunoradiometric assay kit (CIS Bio International, Bagnols-sur-Ceze, France). Once the metastatic or recurrent lesions were detected, surgery, external radiotherapy, or 131I therapy was recommended.

Admission records were surveyed and the following data were stored in the computer: age, sex, primary tumor size, ultrasonographic findings, FNAC results, thyroid function before operation, operative methods, histopathological findings, TNM staging, 1-month postoperative serum Tg levels, results of diagnostic and therapeutic 131I scans, postoperative chest radiography findings, clinical status for analysis of distant metastases by noninvasive examinations, treatment results, causes of death, and survival status. Statistical significance corresponded to \( P \leq 0.05 \). Actuarial survival rates were calculated by the Breslow-Meier method, and differences in survival rates were examined with the Breslow and Mantel-Cox tests.

Most patients in the 3 groups received nearly total thyroidectomy after diagnosis of PTM before or during the operation (Figure 3). In contrast to groups 1 and 2, most group 3 cases received subtotal thyroidectomy because PTM was identified incidentally on final histopathological examination. Twenty-two of the 101 patients in group 3 underwent nearly total thyroidectomy, including those who underwent secondary operation for total thyroidectomy. In this study, the mean \( \pm SD \) age of the 227 patients with PTM (40.6 \( \pm \) 12.4 years) paralleled that of patients with larger tumors (40.4 \( \pm \) 14.7 years). No difference in age and sex distribution of patients with PTM was apparent when compared with 1143 patients with larger tumors. Pathological review showed 20 patients with multicentric PTM, 3 with lymphocytic thyroiditis, 2 with a follicular variant of papillary thyroid carcinoma, and 1 with an insular pattern. Among these patients, 1 displayed a multicentric, follicular variant and poorly differentiated patterns simultaneously. Clinical variables were compared between the 207 nonmulticentric and 20 multicentric cases of PTM. The results indicated higher ratios of multicentric PTM in male patients (6 of 31 men vs 14 of 196 women; \( P = 0.03 \)). Otherwise, age, tumor size, follow-up status, and TNM staging showed no statistical difference between the 2 groups.

In the present study, after 9.6 years of follow-up, 6 patients had died. Only 0.9% of the patients with PTM (2 of 227) died of thyroid cancer. One patient who died of thyroid cancer was a 74-year-old woman who appeared with skull metastases and microcarcinoma measuring 1 cm in her thyroid. The patient underwent nearly total thyroidectomy, removal of the skull tumor, and external radiation to the skull and brain. She died 1 year 10 months after the thyroidectomy. The other case was a 43-year-old man diagnosed as having a follicular variant of PTM with vertebral metastases. Multicentric and poorly differentiated patterns were found in the histopathologic findings. After surgical treatment with a total of 500 mCi (18 500 MBq) of 131I treatments, the patient died 5 years later. Of 227 patients with PTM, 4 (1.8%) displayed distant metastases at surgery. Among these patients, 3 had bone metastases. Lung metastases were indicated by 131I scanning and elevated Tg levels in 1 of the patients with PTM.

Table 1 gives the characteristics of the 227 patients with PTM, categorized according to histopathological findings. There were 189 cases of microcarcinoma restricted to the thyroid, 22 of lymph node metastases, and 16 of extrathyroid extension, including soft-tissue invasion and distant metastases. Patients with extrathyroid involvement were demonstrably older. Sex, surgical meth-
ods, follow-up status, and mortality due to thyroid cancer did show differences between these groups.

Clinical assessment was compared among the 3 groups diagnosed at different periods (Table 2). Of the 227 patients, 193 received serum Tg examinations, with a mean±SD Tg level of 21.0±4.8 ng/mL. Although postoperative 131I uptake was higher in group 3 because of less aggressive surgical procedures, Tg levels otherwise lacked statistically significant differences among the 3 groups. Comparison of mean postoperative Tg levels of patients with tumors restricted to the thyroid and the group with lymph node metastases illustrated a statistically significant difference (Table 1).

Among groups 1, 2, and 3, 18% (9/51), 17% (13/75), and 78% (79/101) of patients, respectively, underwent subtotal thyroidectomy or lobectomy for tumors. The accuracy of preoperative aspiration cytology was only 30.4% (51/168 cases). One hundred seventeen cases were unable to be diagnosed by preoperative ultrasonography and FNAC. Patients who had frozen sections taken during surgery received the correct diagnosis in 74.2% (118/159) of cases (Figure 2). Of the 227 patients, 37 received neither FNAC nor frozen section during surgery. Table 3 illustrates clinical characteristics of PTM categorized into high-risk (12 patients) and low-risk (215 patients) groups. Age, sex, operative methods, Tg level, follow-up status, and survival differed significantly between the 2 groups. Mean±SD tumor sizes of the low- and high-risk groups were 0.64±0.02 cm and 0.77±0.06 cm, respectively (P=.12). After treatment, no patients in the low-risk group died.

Figure 2. Distribution of 227 patients with papillary thyroid microcarcinoma (PTM) at the time of diagnosis across 3 groups. FNAC indicates fine-needle aspiration cytology.

Figure 3. Treatment results for 227 patients with papillary thyroid microcarcinoma in 3 groups. FNAC indicates fine-needle aspiration cytology; 131I, iodine I 131; DE, number of patients with extrathyroid findings at diagnosis; R, number of patients with clinical relapse; PN, number of patients whose present status was non–disease free; and M, number of patients who died. To convert 131I doses to megabecquerels, multiply by 37.
risk group died of thyroid cancer. Figure 4 demonstrates the Kaplan-Meier survival curves of these 2 groups. Two patients in the high-risk group died of thyroid cancer. Eight of the 12 patients in the high-risk group were in disease-free survival during the follow-up period.

Among the 227 cases, 149 received a higher dose of ¹³¹I therapy for ablation of the remnant or treatment for distant metastases (¹³¹I dose ≥30 mCi [≥1110 MBq] in Figure 3). One hundred twenty-six patients received nearly total thyroidectomy followed by thyroid remnant ablation with ¹³¹I treatment. Thirty of the 126 patients showed lymph node or extrathyroid involvement in the histologic finding. Of the 102 patients who showed evidence of not being disease free during the follow-up period, and 2 cases resulted in mortality from thyroid cancer. Fifty-four patients received subtotal thyroidectomy without ¹³¹I ablation treatment. No recurrence or mortality due to thyroid cancer occurred.

**Table 1. Clinical Characteristics of PTM Not Confined to Thyroid**

<table>
<thead>
<tr>
<th>Age at diagnosis, mean ± SD, y</th>
<th>40.3 ± 12.2</th>
<th>35.6 ± 10.8</th>
<th>49.3 ± 13.4</th>
<th>B, C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, No. F/M (ratio)</td>
<td>168/21 (8.0:1)</td>
<td>16/6 (2.7:1)</td>
<td>12/4 (3.0:1)</td>
<td>.04</td>
</tr>
<tr>
<td>Operative method, No. subtotal/nearly total thyroidectomy (ratio)</td>
<td>99/80 (1.1:1)</td>
<td>0/22 (0)</td>
<td>2/14 (0.1:1)</td>
<td>.001</td>
</tr>
<tr>
<td>Tumor size, mean ± SD, cm</td>
<td>0.61 ± 0.02</td>
<td>0.79 ± 0.05</td>
<td>0.84 ± 0.05</td>
<td>A, B</td>
</tr>
<tr>
<td>Tg 1 mo after operation, mean ± SD, ng/mL</td>
<td>14.5 ± 1.6</td>
<td>5.7 ± 2.5</td>
<td>5.2 ± 1.4</td>
<td>.049</td>
</tr>
<tr>
<td>Present status, No. disease free/non–disease free (ratio)</td>
<td>189/0 (NA)</td>
<td>21/1 (21:1)</td>
<td>12/4 (3.0:1)</td>
<td>.001</td>
</tr>
<tr>
<td>Survival, No. yes/no (ratio)</td>
<td>185/4 (46.3:1)</td>
<td>22/0 (NA)</td>
<td>14/2 (7.0:1)</td>
<td>.001</td>
</tr>
</tbody>
</table>

**Table 2. Classification of PTM Before, During, and After Operation**

<table>
<thead>
<tr>
<th>Time of PTM Finding (n = 227)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preoperative Diagnosis (FNAC)</td>
</tr>
<tr>
<td>(n = 51)</td>
</tr>
<tr>
<td>Age, mean ± SD, y</td>
</tr>
<tr>
<td>Operative method, No. subtotal/nearly total thyroidectomy (ratio)</td>
</tr>
<tr>
<td>Tumor size, mean ± SD, cm</td>
</tr>
<tr>
<td>Tg 1 mo after operation, mean ± SD, ng/mL</td>
</tr>
<tr>
<td>TNM stage, No. stage 1/stages 2-4 (ratio)</td>
</tr>
<tr>
<td>Present status, No. disease free/non–disease free (ratio)</td>
</tr>
</tbody>
</table>

**Abbreviations:** FNAC, fine-needle aspiration cytology; ¹³¹I, iodine I ¹³¹; PTM, papillary thyroid microcarcinoma; Tg, thyroglobulin.

**Abbreviations:** ¹³¹I, iodine I ¹³¹; NA, not applicable; PTM, papillary thyroid microcarcinoma; Tg, thyroglobulin.

©2005 American Medical Association. All rights reserved.
been reported that females have a superior survival rate.20,21

Extrathyroid involvement at presentation and there was a greater percentage of male patients in the high-risk group. Only 2 cases resulted in mortality. More cases and long-term follow-up are required to realize the influence of sex on the prognosis of papillary thyroid carcinoma. Most reports in the literature have shown that older patients with well-differentiated thyroid carcinomas had a worse prognosis.8,9,20 As in this study, mean age was greater in the high-risk group; otherwise, age did not significantly affect aggressiveness or metastases of PTM.23

An earlier work reported that Tg level could be used as a tumor marker for follow-up of patients with well-differentiated thyroid cancer.24 Although tumor recurrence has been detected by elevation of serum Tg level after surgery,25,26 there was limited information about serum Tg level as a prognostic factor in patients with PTM. Although 1-month postoperative serum Tg levels showed no difference between patients with papillary microcarcinoma and those with larger tumors, there was a significant difference between groups with tumor localized in the thyroid and extrathyroid invasion. Earlier investigation confirmed that serum Tg levels below 2 ng/mL in patients receiving thyroid hormone replacement, or 3 ng/mL in those without replacement therapy, were infrequently associated with tumor recurrence.26 Thyroglobulin remains an important postoperative tumor marker in patients with PTM.

Among the 227 patients with PTM, 117 (51.5%) were younger than 45 years old, 121 (53.4%) were female, and 119 (52.6%) were male. Familial PTM has been mentioned as a new clinical entity,14,15 but in the present study, only 1 case entailed family history of thyroid cancer. As in earlier studies, patients with PTM had a rather benign clinical course.16,17 Less than 1% died of PTM, and 5 of 227 were non–disease free.

The male–female distribution of thyroid cancer was 1:6.3, a ratio higher than in previous studies.14,18,19 It has been reported that females have a superior survival rate.20,21 In a study by Schindler et al.,22 univariate analysis showed that, although men had a higher recurrence rate of papillary thyroid carcinoma, sex was not significant in multivariate analysis. In the current study, of male subjects with more aggressive PTM patterns, one third showed

<table>
<thead>
<tr>
<th>Table 3. Clinical Characteristics of PTM Categorized Into High- or Low-Risk Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Risk (n = 215)</td>
</tr>
<tr>
<td>Age at diagnosis, mean ± SD, y</td>
</tr>
<tr>
<td>Sex, No. F/M (ratio)</td>
</tr>
<tr>
<td>Operative method, No. subtotal/nearby total thyroidectomy (ratio)</td>
</tr>
<tr>
<td>131I uptake 1 mo after operation, mean ± SD, %</td>
</tr>
<tr>
<td>Tg 1 mo after operation, mean ± SD, ng/mL</td>
</tr>
<tr>
<td>Present status, No. disease free/non–disease free (ratio)</td>
</tr>
<tr>
<td>Survival, No. yes/no (ratio)</td>
</tr>
</tbody>
</table>

Abbreviations: 131I, iodine 131; PTM, papillary thyroid microcarcinoma; Tg, thyroglobulin.
*Only compared patients who died of thyroid cancer and patients who survived (215/0 vs 10/2).
†Only compared patients who died of causes other than thyroid cancer.
treatment. Until now, no consensus existed for aggressive treatment including \( ^{131} \text{I} \), reoperation, or external radiotherapy if extrathyroid invasion of PTM was found in the first operation. From a clinical practice viewpoint, after appropriate preoperative evaluation, subtotal thyroidectomy may be performed in PTM localized in the thyroid and total thyroidectomy performed in cases with extrathyroid invasion. In this study, about 45% (101/227) of cases of PTM were diagnosed after operation. Around 9% (9 of the 101 cases) were proved to have extrathyroid involvement on final histopathologic examination. In a recent study by Ito et al., an observation trial without surgical treatment in PTM was conducted in Japan. In this study, 16.6% of cases of papillary thyroid cancer were PTM. Although most patients with PTM had a benign clinical course, distant metastases causing mortality were occasionally observed. Age, sex, and postoperative Tg level were the main prognostic factors in the high-risk group of patients with PTM. Earlier diagnosis with timely surgical removal of high-risk tumors before distant metastases develops may help improve the prognosis in these patients.

Accepted for Publication: November 2, 2004.

Correspondence: Jen-Der Lin, MD, Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital, 5, Fu-Shin St Kweishan County, Taoyuan Hsien, Taiwan (eijnd@adm.cgmh.org.tw).

REFERENCES


